USA Financial Formulas Boosts Position in Gilead Sciences, Inc. $GILD

USA Financial Formulas boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 24.1% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 30,176 shares of the biopharmaceutical company’s stock after acquiring an additional 5,858 shares during the quarter. Gilead Sciences accounts for 0.6% of USA Financial Formulas’ portfolio, making the stock its 19th biggest holding. USA Financial Formulas’ holdings in Gilead Sciences were worth $3,346,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of GILD. Southland Equity Partners LLC increased its holdings in shares of Gilead Sciences by 2.9% in the 2nd quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock valued at $364,000 after acquiring an additional 92 shares during the period. Twelve Points Wealth Management LLC increased its holdings in shares of Gilead Sciences by 1.5% in the 2nd quarter. Twelve Points Wealth Management LLC now owns 6,499 shares of the biopharmaceutical company’s stock valued at $721,000 after acquiring an additional 98 shares during the period. Argentarii LLC increased its holdings in shares of Gilead Sciences by 3.0% in the 1st quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company’s stock valued at $380,000 after acquiring an additional 99 shares during the period. Peak Financial Advisors LLC increased its holdings in shares of Gilead Sciences by 1.7% in the 1st quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company’s stock valued at $677,000 after acquiring an additional 100 shares during the period. Finally, Perkins Coie Trust Co increased its holdings in shares of Gilead Sciences by 2.6% in the 1st quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company’s stock valued at $435,000 after acquiring an additional 100 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD opened at $111.15 on Thursday. The stock has a 50-day moving average of $114.47 and a two-hundred day moving average of $109.92. Gilead Sciences, Inc. has a one year low of $83.10 and a one year high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The stock has a market cap of $137.92 billion, a P/E ratio of 22.14, a P/E/G ratio of 0.75 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm’s revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s payout ratio is 62.95%.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the transaction, the chief financial officer owned 159,555 shares of the company’s stock, valued at $18,120,661.35. The trade was a 1.54% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $109.74, for a total value of $548,700.00. Following the completion of the transaction, the director directly owned 8,920 shares of the company’s stock, valued at approximately $978,880.80. This trade represents a 35.92% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 82,000 shares of company stock worth $9,402,130. Corporate insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on GILD shares. Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. UBS Group lifted their price target on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a report on Friday, August 8th. Daiwa Capital Markets raised Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price objective for the company in a research report on Tuesday, August 19th. Needham & Company LLC raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective for the company in a research report on Friday, July 25th. Finally, Truist Financial raised Gilead Sciences from a “hold” rating to a “buy” rating and raised their price objective for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $117.17.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.